We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
IBA-Radcal

Download Mobile App




Cholesterol-Lowering Drug an Unexpected Antibiotic

By HospiMedica staff writers
Posted on 26 Feb 2008
Microbiologists have found that treating Staphylococcus aureus with a cholesterol-lowering drug inhibited the synthesis of the golden-colored pigment staphyloxanthin, and rendered the bacteria more susceptible to destruction by the immune system.

An international team of investigators based their attack on S. More...
aureus on earlier findings that a strain of the bacteria lacking the golden pigment was easier to kill. Since the pathway for production of staphyloxanthin in the bacteria is similar to that for synthesis of cholesterol in humans, the investigators examined the effect of drugs that inhibit cholesterol synthesis.

They reported in the February 14, 2008, online edition of the journal Science that of eight different drug compounds tested, three blocked pigment production in S. aureus. Treatment of mice infected with S. aureus with one of the compounds reduced bacterial population by 98%.

Since stopping pigment production caused the reduction in virulence, this treatment may not cause selective pressures on the population, which often leads to antibiotic resistance. Furthermore, this method targets only S. aureus, reducing possible side effects.

"I looked at the metabolic pathway and noticed that it was similar to the one for the production of cholesterol in humans,” said Dr. Eric Oldfield, professor of chemistry at the University of Illinois (Urbana-Champaign, USA). "This is an entirely new approach that seems to work in animals, and now we need to take the next step to explore if it will work in humans.”


Related Links:
University of Illinois

Gold Member
SARS‑CoV‑2/Flu A/Flu B/RSV Sample-To-Answer Test
SARS‑CoV‑2/Flu A/Flu B/RSV Cartridge (CE-IVD)
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
IV Therapy Cart
Avalo I.V Therapy Cart
LED Surgical Lamp
ACEMST35/57
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Surgical Techniques

view channel
Image: The fiber in the brain implant is less than half a millimeter thick (Photo courtesy of Peter Aagaard Brixen)

Brain Implant Records Neural Signals and Delivers Precise Medication

Neurological diseases such as epilepsy involve complex interactions across multiple layers of the brain, yet current implants can typically stimulate or record activity from only a single point.... Read more

Patient Care

view channel
Image: The revolutionary automatic IV-Line flushing device set for launch in the EU and US in 2026 (Photo courtesy of Droplet IV)

Revolutionary Automatic IV-Line Flushing Device to Enhance Infusion Care

More than 80% of in-hospital patients receive intravenous (IV) therapy. Every dose of IV medicine delivered in a small volume (<250 mL) infusion bag should be followed by subsequent flushing to ensure... Read more

Business

view channel
Image: Medtronic’s intent to acquire CathWorks follows a 2022 strategic partnership with a co-promotion agreement for the FFRangio System (Photo courtesy of CathWorks)

Medtronic to Acquire Coronary Artery Medtech Company CathWorks

Medtronic plc (Galway, Ireland) has announced that it will exercise its option to acquire CathWorks (Kfar Saba, Israel), a privately held medical device company, which aims to transform how coronary artery... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.